Edition:
United Kingdom

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

81.19USD
8:00pm BST
Change (% chg)

$0.63 (+0.78%)
Prev Close
$80.56
Open
$80.46
Day's High
$81.29
Day's Low
$79.99
Volume
149,972
Avg. Vol
675,992
52-wk High
$82.25
52-wk Low
$61.06

Latest Key Developments (Source: Significant Developments)

Third Point Llc Reports Stake Of 4.5% In Baxter International
Friday, 17 May 2019 

May 17 (Reuters) - Third Point Llc::THIRD POINT LLC REPORTS A STAKE OF 4.5% IN BAXTER INTERNATIONAL AS OF MAY 16, 2019 - SEC FILING.THIRD POINT LLC - DO NOT CURRENTLY CONTEMPLATE FURTHER SALES OF BAXTER'S SHARES FOR AT LEAST 90 DAYS.THIRD POINT LLC HAD EARLIER REPORTED A STAKE OF 5.3% IN BAXTER INTERNATIONAL AS OF DEC 3, 2018.  Full Article

Baxter Reports First-Quarter 2019 Results
Thursday, 25 Apr 2019 

April 25 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL QTRLY EARNINGS PER SHARE $0.66 .BAXTER REPORTS FIRST-QUARTER 2019 RESULTS.Q1 GAAP EARNINGS PER SHARE $0.66.Q1 REVENUE $2.6 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.61 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.68 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.27 TO $3.35 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q2 2019 ADJUSTED EARNINGS PER SHARE $0.80 TO $0.82 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.WORLDWIDE SALES IN Q1 TOTALED APPROXIMATELY $2.6 BILLION, A DECREASE OF 2% ON A REPORTED BASIS.BAXTER IS RAISING ITS EARNINGS OUTLOOK FOR 2019..QTRLY ADJUSTED EPS OF $0.76.CONTINUES TO EXPECT SALES GROWTH OF 0 TO 1 PERCENT ON A REPORTED BASIS IN 2019.FOR Q2 COMPANY EXPECTS SALES TO DECLINE APPROXIMATELY 2 PERCENT ON A REPORTED BASIS.SEES Q2 2019 ADJUSTED EARNINGS FROM CONTINUING OPERATIONS, BEFORE SPECIAL ITEMS, OF $0.80 TO $0.82 PER DILUTED SHARE.Q2 EARNINGS PER SHARE VIEW $0.82, REVENUE VIEW $2.83 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $3.28, REVENUE VIEW $11.22 BILLION -- REFINITIV IBES DATA.  Full Article

Baxter International Inc Says Carole Shapazian To Retire From Board
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL INC - CAROLE SHAPAZIAN NOTIFIED CO OF HER DECISION TO RETIRE FROM THE BOARD OF DIRECTORS OF THE COMPANY.BAXTER INTERNATIONAL INC - MUNIB ISLAM NOTIFIED THE COMPANY OF HIS DECISION TO RESIGN FROM THE BOARD.BAXTER INTERNATIONAL INC - MUNIB ISLAM HAD ORIGINALLY BEEN APPOINTED TO THE BOARD AS A REPRESENTATIVE OF THIRD POINT LLC.BAXTER - IN CONNECTION WITH RESIGNATION, MUNIB ISLAM STATED, AS PRINCIPAL OF THIRD POINT, "THAT THIRD POINT IS ENTHUSIASTIC ABOUT BAXTER’S DIRECTION".  Full Article

Third Point LLC Cuts Share Stake in American Express and Baxter, Dissolves in Alibaba
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Third Point LLC::THIRD POINT LLC DISSOLVES SHARE STAKE IN ALIBABA GROUP HOLDING LTD - SEC FILING.THIRD POINT LLC DISSOLVES SHARE STAKE IN LENNAR CORP.THIRD POINT LLC CUTS SHARE STAKE IN PAYPAL HOLDINGS INC BY 55.5 PERCENT TO 4.0 MILLION SHARES.THIRD POINT LLC UPS SHARE STAKE IN SALESFORCE COM INC TO 1.2 MILLION SHARES FROM 500,000 SHARES.THIRD POINT LLC CUTS SHARE STAKE IN AMERICAN EXPRESS CO BY 42.0 PERCENT TO 2.9 MILLION SHARES.THIRD POINT LLC CUTS SHARE STAKE IN BAXTER INTERNATIONAL INC BY 22.2 PERCENT TO 28.0 MILLION SHARES.THIRD POINT LLC - CHANGE IN HOLDINGS ARE AS OF DECEMBER 31, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF SEPTEMBER 30, 2018.  Full Article

Baxter And Premier's Subsidiary To Make Additional Generic Drugs Available
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Baxter International Inc ::BAXTER AND PREMIER’S PROVIDEGX™ SUBSIDIARY COLLABORATE TO ADDRESS DRUG SHORTAGES.PREMIER INC - PROVIDEGX IS COLLABORATING WITH BAXTER HEALTHCARE CORPORATION TO MAKE ADDITIONAL GENERIC DRUGS AVAILABLE FOR PURCHASE.PREMIER INC - FINANCIAL TERMS OF PREMIER'S DEAL WITH BAXTER WERE NOT DISCLOSED..PREMIER INC - REVENUES FROM PARTNERSHIP ARE NOT EXPECTED TO MATERIALLY IMPACT PREMIER FY 2019 RESULTS..PREMIER INC - REVENUES FROM PARTNERSHIP ARE NOT EXPECTED TO MATERIALLY IMPACT PREMIER FY 2019 RESULTS.  Full Article

UK's CMA Decides Not To Refer Baxter-Hospira Deal To Phase 2 Investigation
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - UK's Competition and Markets Authority (CMA)::DECIDED NOT TO REFER BAXTER INTERNATIONAL-HOSPIRA UK DEAL TO PHASE 2 INVESTIGATION UNDER PROVISIONS OF ENTERPRISE ACT 2002.  Full Article

Prescient Surgical Raises $10 Million In Series B Investment
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Baxter International Inc ::PRESCIENT SURGICAL RAISES $10 MILLION IN SERIES B INVESTMENT.PRESCIENT SURGICAL SAYS FUNDING ROUND WAS LED BY BAXTER VENTURES, VENTURE INVESTMENT ARM OF BAXTER INTERNATIONAL, INC.  Full Article

Baxter Reports Third-Quarter 2018 Results
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Baxter International Inc ::BAXTER REPORTS THIRD-QUARTER 2018 RESULTS AND UPDATES FINANCIAL OUTLOOK FOR FULL-YEAR 2018.Q3 GAAP EARNINGS PER SHARE $1.00 FROM CONTINUING OPERATIONS.Q3 REVENUE $2.8 BILLION VERSUS I/B/E/S VIEW $2.78 BILLION.Q3 EARNINGS PER SHARE VIEW $0.74 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $2.98 TO $3.00 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES Q4 2018 ADJUSTED EARNINGS PER SHARE $0.71 TO $0.73 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2018 GAAP EARNINGS PER SHARE $2.90 TO $2.94.COMPANY EXPECTS FULL-YEAR 2018 SALES GROWTH OF APPROXIMATELY 5 PERCENT ON A REPORTED BASIS.COMPANY EXPECTS FULL-YEAR 2018 SALES GROWTH OF APPROXIMATELY 3 PERCENT ON AN OPERATIONAL BASIS.FY2018 EARNINGS PER SHARE VIEW $2.98, REVENUE VIEW $11.20 BILLION -- THOMSON REUTERS I/B/E/S.BAXTER INTERNATIONAL - QTRLY WORLDWIDE SALES TOTALED ABOUT $2.8 BILLION, UP 2 PERCENT ON A REPORTED BASIS, 3 PERCENT ON A CONSTANT CURRENCY BASIS."EXPERIENCED A SLOWER-THAN-EXPECTED RETURN TO PRE-HURRICANE MARIA PURCHASING LEVELS ACROSS CERTAIN BUSINESSES".QTRLY ADJUSTED EPS OF $0.80.BAXTER INTERNATIONAL - QTRLY RESULTS INCLUDED SPECIAL ITEMS $108 MILLION, RELATED TO BUSINESS OPTIMIZATION AND INTANGIBLE AMORTIZATION.QTRLY RESULTS INCLUDED $200 MILLION BENEFIT RELATED TO U.S. FOREIGN TAX CREDIT DEFERRED TAX ASSETS.SAW IMPACT FROM DISTRIBUTOR DESTOCKING FOR SELECT PRODUCTS THAT HAS "DEPRESSED" TOP-LINE PERFORMANCE IN 2018.  Full Article

Baxter Receives CE Mark For Prismax
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Baxter International Inc ::BAXTER RECEIVES CE MARK FOR PRISMAX, THE NEXT-GENERATION SYSTEM FOR CONTINUOUS RENAL REPLACEMENT AND ORGAN SUPPORT THERAPIES.BAXTER INTERNATIONAL - NEW THERMAX BLOOD WARMER ALSO RECEIVES CE MARK TO DELIVER EFFECTIVE BLOOD WARMING FOR A VARIETY OF ORGAN SUPPORT THERAPIES.  Full Article

Baxter Announces U.S. FDA Clearance Of New Bone Graft Substitute, Actifuse Flow
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES U.S. FDA CLEARANCE OF NEW BONE GRAFT SUBSTITUTE, ACTIFUSE FLOW.BAXTER INTERNATIONAL INC - EXPECTS ACTIFUSE FLOW TO BE AVAILABLE TO U.S. CUSTOMERS BY YEAR-END.  Full Article

U.S. closes IV solution shortage antitrust probe, Baxter says

Feb 22 Baxter International Inc said the U.S. Justice Department has closed an antitrust probe examining possible communication among producers of intravenous saline solutions during supply shortages that created higher prices.